| Clinical data | |
|---|---|
| Other names | PD-0299685; PD-299685; PD0299685; PD299685; PD-299,685 |
| Routes of administration | Oral[1] |
| Drug class | Gabapentinoid |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H21NO2 |
| Molar mass | 187.283 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PD-0299685 is agabapentinoid (α2δ subunit-containingvoltage-gated calcium channelblocker) which was under development for the treatment ofinsomnia andvasomotor symptoms (hot flashes) related tomenopause as well asinterstitial cystitis.[1][2][3] It is takenorally.[1] PD-0299685 was under development byPfizer.[1] It reachedphase 2clinical trials prior to the discontinuation of its development.[1]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |